154 related articles for article (PubMed ID: 26707610)
1. Vesicular stomatitis virus is a potent agent for the treatment of malignant ascites.
Zhou Y; Wen F; Zhang P; Tang R; Li Q
Oncol Rep; 2016 Mar; 35(3):1573-81. PubMed ID: 26707610
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
[TBL] [Abstract][Full Text] [Related]
3. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
4. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
5. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
6. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer.
Day GL; Bryan ML; Northrup SA; Lyles DS; Westcott MM; Stewart JH
J Surg Res; 2020 Jan; 245():127-135. PubMed ID: 31415934
[TBL] [Abstract][Full Text] [Related]
7. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.
Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL
Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874
[TBL] [Abstract][Full Text] [Related]
9. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
13. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers.
Fehl DJ; Ahmed M
Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.
Le Boeuf F; Niknejad N; Wang J; Auer R; Weberpals JI; Bell JC; Dimitroulakos J
Int J Cancer; 2012 Aug; 131(3):E204-15. PubMed ID: 22173567
[TBL] [Abstract][Full Text] [Related]
15. Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling.
Malilas W; Koh SS; Srisuttee R; Boonying W; Cho IR; Jeong CS; Johnston RN; Chung YH
Cancer Gene Ther; 2013 Feb; 20(2):125-32. PubMed ID: 23306614
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
[TBL] [Abstract][Full Text] [Related]
17. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo.
Connor JH; Naczki C; Koumenis C; Lyles DS
J Virol; 2004 Sep; 78(17):8960-70. PubMed ID: 15308693
[TBL] [Abstract][Full Text] [Related]
18. Matrix protein of vesicular stomatitis virus: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation.
Zhou Y; Wen F; Zhang P; Tang R; Li Q
Cancer Gene Ther; 2013 Mar; 20(3):178-85. PubMed ID: 23449478
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.
Ammayappan A; Peng KW; Russell SJ
J Virol; 2013 Dec; 87(24):13543-55. PubMed ID: 24089573
[TBL] [Abstract][Full Text] [Related]
20. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.
Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D
Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
